ПРОГНОЗИРОВАНИЕ ЭФФЕКТИВНОСТИ ТОЦИЛИЗУМАБА И РИТУКСИМАБА ПРИ РЕВМАТОИДНОМ АРТРИТЕ



DOI: http://dx.doi.org/10.25298/2221-8785-2019-17-5-560-564


М. В. Волкова (M. V. Volkava)

Аннотация


Цель. Изучить возможность прогнозирования эффективности лечения тоцилизумабом и ритуксимабом при ревматоидном артрите (РА) с учетом клинико-иммунологических особенностей пациентов.
Материал и методы. Проанализирована эффективность лечения тоцилизумабом у 53 пациентов и ритуксимабом – у 22 пациентов с РА в течение 12 месяцев, оценена прогностическая роль исходных значений индексов активности, наличия системных проявлений, длительности РА, уровней аутоантител, острофазовых белков.
Результаты. Установлена высокая эффективность лечения биологическими лекарственными средствами при РА в исследуемой выборке, цели лечения достигли 84,91% пациентов в группе тоцилизумаба и 72,72% в группе ритуксимаба, однако оставшиеся пациенты не достигли цели лечения через 12 месяцев наблюдения.
Выводы. Достоверными предикторами хорошего ответа на тоцилизумаб при РА могут служить высокая активность суставного синдрома, на ритуксимаб – серопозитивный вариант РА, а также наличие системных проявлений.

Ключевые слова


ревматоидный артрит, тоцилизумаб, ритуксимаб, эффективность лечения, предикторы

Полный текст:

Литература


2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative / D. Aletaha [et al.] // Arthritis Rheum. – 2010. – Vol. 62, iss. 9. – P. 2569-2581. – doi: 10.1002/art.27584.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update / J. S. Smolen [et al.] // Ann. Rheum. Dis. – 2017. – Vol. 76, iss. 6. – P. 960-977. – doi: 10.1136/annrheumdis-2016-210715.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis / J. L. Nam [et al.] // Ann. Rheum. Dis. – 2017. – Vol. 76, iss. 6. – P. 1113-1136. – doi: 10.1136/annrheumdis-2016-210713.

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 2017;76(6):1113-1136. doi: 10.1136/annrheumdis-2016-210713.

Singh, J. A. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review / J. A. Singh, S. Beg, M. A. Lopez-Olivo // J. Rheumatol. – 2011. – Vol. 38, iss. 1. – P. 10-20. – doi: 10.3899/jrheum.100717.

Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 2011;38(1):10-20. doi: 10.3899/jrheum.100717.

Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis / R. Alfonso-Cristancho [et al.] // Clin. Rheumatol. – 2017. – Vol. 36, iss. 1. – P. 25-34. – doi: 10.1007/s10067-016-3435-2.

Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, Kleijnen J. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin. Rheumatol. 2017;36(1):25-34. doi: 10.1007/s10067-016-3435-2.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial / C. Gabay [et al.] // Lancet. – 2013. – Vol. 381, iss. 9877. – P. 1541-1550. – doi: 10.1016/S0140-6736(13)60250-0.

Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541-1550. doi: 10.1016/S0140-6736(13)60250-0.

Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance / M. R. Smith // Oncogene. – 2003. – Vol. 22, iss. 47. – P. 7359-7368. – doi: 10.1038/sj.onc.1206939.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368. doi: 10.1038/sj.onc.1206939.

Assmann, G. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers / G. Assmann, M. Pfreundschuh, J. Voswinkel // Clin. Exp. Rheumatol. – 2010. – Vol. 28, iss. 1, suppl. 57. – P. 81-83.

Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin. Exp. Rheumatol. 2010;28(1 Suppl 57):81-83.

Chandra, P. A. Rituximab is useful in the treatment of Felty's syndrome / P. A. Chandra, Y. Margulis, C. Schiff // Am. J. Ther. – 2008. – Vol. 15, iss. 4. – P. 321-322. – doi: 10.1097/MJT.0b013e318164bf32.

Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty's syndrome. Am. J. Ther. 2008;15(4):321-322. doi: 10.1097/MJT.0b013e318164bf32.

Rituximab treatment for persistent scleritis associated with rheumatoid arthritis / B. Iaccheri [et al.] / Ocul. Immunol. Infamm. – 2010. – Vol. 18, iss. 3. – P. 223-225. – doi: 10.3109/09273941003739928.

Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul. Immunol. Infamm. 2010;18(3):223-225. doi: 10.3109/09273941003739928.

American College of Rheumatology/European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials / D. T. Felson [et al.] // Arthritis Rheum. – 2011. – Vol. 63, iss. 3. – P. 573-586. – doi: 10.1002/art.30129.

Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, et al. American College of Rheumatology/European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Arthritis Rheum. 2011;63(3):573-586. doi: 10.1002/art.30129.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis / M. L. Prevoo [et al.] // Arthritis Rheum. – 1995. – Vol. 38, iss. 1. – P. 44-48. – doi: 10.1002/art.1780380107.

Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48. doi: 10.1002/art.1780380107.


Ссылки

  • На текущий момент ссылки отсутствуют.